drugset / Trial / NCT06598306
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Non-randomizedSequentialOpen-labelBasic science
Summary
The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.
Timeline
- Start
- 2024-10-07
- Primary completion
- 2027-04-24
- Completion
- 2030-04-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tarlatamab | Protein / enzyme biologic | — | Subcutaneous |